Target:C9
Fields:Complement and coagulation cascades;Prion disease;Amoebiasis;Coronavirus disease - COVID-19;Systemic lupus erythematosus
Gene Name:C9
Protein Name:Complement component C9
Human Gene Id:735
Human Swiss Prot No:P02748
Mouse Swiss Prot No:P06683
Immunogen:The antiserum was produced against synthesized peptide derived from human C9. AA range:181-230
Specificity:C9 Polyclonal Antibody detects endogenous levels of C9 protein.
Formulation:Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source:Polyclonal, Rabbit,IgG
Dilution:WB 1:500 - 1:2000. ELISA: 1:40000. Not yet tested in other applications.
Purification:The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration:1 mg/ml
Storage Stability:-15°C to -25°C/1 year(Do not lower than -25°C)
Other Name:C9;Complement component C9
Observed Band(KD):70kD
Background: This gene encodes the final component of the complement system. It participates in the formation of the Membrane Attack Complex (MAC). The MAC assembles on bacterial membranes to form a pore, permitting disruption of bacterial membrane organization. Mutations in this gene cause component C9 deficiency. [provided by RefSeq, Feb 2009],
Function:disease:Defects in C9 are a cause of component C9 deficiency (C9D) [MIM:120940]. Patients with C9D suffer from recurrent bacterial infections, predominantly from Neisseria meningitidis.,function:C9 is the final component of the complement system to be added in the assembly of the membrane attack complex. It is able to enter lipid bilayers, forming transmembrane channels.,online information:C9 mutation db,PTM:Thrombin cleaves factor C9 to produce C9a and C9b.,similarity:Belongs to the complement C6/C7/C8/C9 family.,similarity:Contains 1 EGF-like domain.,similarity:Contains 1 LDL-receptor class A domain.,similarity:Contains 1 MACPF domain.,similarity:Contains 1 TSP type-1 domain.,
Subcellular Location:Secreted . Target cell membrane ; Multi-pass membrane protein . Secreted as soluble monomer. Oligomerizes at target membranes, forming a pre-pore. A conformation change then leads to the formation of a 100 Angstrom diameter pore. .
Expression:Plasma (at protein level).